Table 2.

β5 overexpression found in cancer cells in response to bortezomib treatment

Cell lines	Overexpression	Fold difference	Ref.
Jurkat	PSMB5 mRNA (CT-L activity increased)	Exposed to bortezomib for 6 months	Lu et al.[44]
THP1	β5	~50 (β5 activity)	Oerlemans et al.[30]
HepG2 HuH7	β5, β1	~15 (cell viability) ~39 (cell viability)	Wu et al.[45]
U266 JJN3	β5 (& β6)	~2–8 (cell viability)	Shi et al.[35]
Primary MM	β5, β6, β6
L363 MM.1S AMO1	β5, β1	9 Against ixazomib 13 11	Brünnert et al.[36]
Primary MM	PSMB5 mRNA	~5 (mRNA)	Shuqing et al.[46]
Primary TNBC	PSMB5 mRNA CT-L activity	Not determined (PSMB5 is indicative of poor prognosis)	Wei et al.[47]